Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Literature DB >> 12121963

In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Eric Dannaoui¹, Javier Afeltra, Jacques F G M Meis, Paul E Verweij.

Abstract

Combinations of antimicrobial agents were tested against 35 strains of zygomycetes. The interaction between amphotericin B and rifampin was synergistic or additive. Flucytosine alone was inactive and, upon combination with amphotericin B, synergy was not achieved. The combination of amphotericin B with terbinafine was synergistic for 20% of strains, and the interaction between terbinafine and voriconazole was synergistic for 44% of strains. Antagonism was not observed.

Entities: Chemical

Mesh：

Substances：

Year: 2002 PMID： 12121963 PMCID： PMC127328 DOI： 10.1128/AAC.46.8.2708-2711.2002

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

39 in total

Review 1. The past, present and future of antimycotic combination therapy.

Authors: A Polak
Journal: Mycoses Date: 1999 Impact factor: 4.377

2. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.

Authors: J Meletiadis; J W Mouton; J L Rodriguez-Tudela; J F Meis; P E Verweij
Journal: Antimicrob Agents Chemother Date: 2000-02 Impact factor: 5.191

3. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.

Authors: A M Sugar; X P Liu
Journal: Antimicrob Agents Chemother Date: 2000-07 Impact factor: 5.191

Review 4. Pulmonary mucormycosis: the last 30 years.

Authors: F Y Lee; S B Mossad; K A Adal
Journal: Arch Intern Med Date: 1999-06-28

5. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.

Authors: L Rodero; S Córdoba; P Cahn; F Hochenfellner; G Davel; C Canteros; S Kaufman; L Guelfand
Journal: J Antimicrob Chemother Date: 2000-02 Impact factor: 5.790

6. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors: M Weig; F M Müller
Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191

7. An evaluation of the in vitro activity of terbinafine.

Authors: C J Jessup; N S Ryder; M A Ghannoum
Journal: Med Mycol Date: 2000-04 Impact factor: 4.076

Review 8. Novel triazole antifungal agents.

Authors: H L Hoffman; E J Ernst; M E Klepser
Journal: Expert Opin Investig Drugs Date: 2000-03 Impact factor: 6.206

Review 9. Zygomycetes in human disease.

Authors: J A Ribes; C L Vanover-Sams; D J Baker
Journal: Clin Microbiol Rev Date: 2000-04 Impact factor: 26.132

Review 10. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases.

Authors: A Pérez
Journal: Mycoses Date: 1999 Impact factor: 4.377

19 in total

Review 1. Antifungal activity of nonantifungal drugs.

Authors: J Afeltra; P E Verweij
Journal: Eur J Clin Microbiol Infect Dis Date: 2003-06-26 Impact factor: 3.267

2. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.

Authors: Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Teresa Peláez; Emilio Bouza
Journal: Antimicrob Agents Chemother Date: 2006-12-28 Impact factor: 5.191

10. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

Authors: Russell E Lewis; Ronen Ben-Ami; Leyla Best; Nathaniel Albert; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal: J Infect Dis Date: 2012-12-13 Impact factor: 5.226

In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Review 1. The past, present and future of antimycotic combination therapy.

2. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.

3. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.

Review 4. Pulmonary mucormycosis: the last 30 years.

5. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.

6. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

7. An evaluation of the in vitro activity of terbinafine.

Review 8. Novel triazole antifungal agents.

Review 9. Zygomycetes in human disease.

Review 10. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases.

Review 1. Antifungal activity of nonantifungal drugs.

2. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.

3. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.

4. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

5. Drug combinations against Mucor irregularis in vitro.

Review 6. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Review 7. Combination treatment of invasive fungal infections.

8. Zygomycosis: an emerging fungal infection with new options for management.

9. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

10. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.